Personalised Cancer Therapeutics
Intelligently Designed
Mass in vivo analysis
Personal Discovery ProcessTM
replicates a patient’s genetic profile and screens thousands of drug cocktails

01 Patient’s entire exome analysed to capture tumour network
02 Mutations comprising patient’s tumour network engineered into fruit fly avatar


03 All FDA approved drugs screened – up to half a million avatars
04 Treatment recommendations report – generally for combination therapy

The Icahn School of Medicine at Mount Sinai developed the PDP methodology over years of clinical research. They found that real-world patient tumours are made resistant to single-drug treatments by mutations in several genes, including genes not previously associated with cancer. Such resistant tumours can however, be effectively addressed with novel combinations of FDA approved drugs. The most effective combinations almost always include non-cancer drugs. The Personal Discovery Process methods are licensed exclusively to My Personal Therapeutics (trading as Vivan Therapeutics).




Our Partners
Backed by




Where to meet us next
Oncology Strategy Meeting Europe 2022
June 14 2022. Click for more details